Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1955 1
1962 1
1964 1
1965 1
1975 10
1976 6
1977 9
1978 13
1979 18
1980 34
1981 53
1982 109
1983 132
1984 197
1985 283
1986 390
1987 462
1988 538
1989 741
1990 761
1991 877
1992 963
1993 1065
1994 1346
1995 1372
1996 1566
1997 1721
1998 1808
1999 1867
2000 2172
2001 2206
2002 2413
2003 2554
2004 2983
2005 3394
2006 3720
2007 3908
2008 4273
2009 4705
2010 5391
2011 5800
2012 6616
2013 7123
2014 7883
2015 8342
2016 7806
2017 7724
2018 9182
2019 9993
2020 11609
2021 13526
2022 13881
2023 13829
2024 4300

Text availability

Article attribute

Article type

Publication date

Search Results

161,923 results

Results by year

Filters applied: . Clear all
Page 1
Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.
Hane FT, Robinson M, Lee BY, Bai O, Leonenko Z, Albert MS. Hane FT, et al. J Alzheimers Dis. 2017;57(3):645-665. doi: 10.3233/JAD-160907. J Alzheimers Dis. 2017. PMID: 28269772 Free PMC article. Review.
The field of Alzheimer's disease (AD) research has grown exponentially over the past few decades, especially since the isolation and identification of amyloid-beta from postmortem examination of the brains of AD patients. Recently, the Journal of Al …
The field of Alzheimer's disease (AD) research has grown exponentially over the past few decades, especially sin …
Clinical Research on Alzheimer's Disease: Progress and Perspectives.
Sun BL, Li WW, Zhu C, Jin WS, Zeng F, Liu YH, Bu XL, Zhu J, Yao XQ, Wang YJ. Sun BL, et al. Neurosci Bull. 2018 Dec;34(6):1111-1118. doi: 10.1007/s12264-018-0249-z. Epub 2018 Jun 28. Neurosci Bull. 2018. PMID: 29956105 Free PMC article. Review.
Alzheimer's disease (AD), the most common type of dementia, is becoming a major challenge for global health and social care. However, the current understanding of AD pathogenesis is limited, and no early diagnosis and disease-modifying therapy are curr …
Alzheimer's disease (AD), the most common type of dementia, is becoming a major challenge for global health and social …
2016 Alzheimer's disease facts and figures.
Alzheimer's Association. Alzheimer's Association. Alzheimers Dement. 2016 Apr;12(4):459-509. doi: 10.1016/j.jalz.2016.03.001. Alzheimers Dement. 2016. PMID: 27570871
The actual number of deaths to which Alzheimer's disease contributes is likely much larger than the number of deaths from Alzheimer's disease recorded on death certificates. In 2016, an estimated 700,000 Americans age 65 years will die wi …
The actual number of deaths to which Alzheimer's disease contributes is likely much larger than the number of deaths fr …
Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus.
Bettcher BM, Tansey MG, Dorothée G, Heneka MT. Bettcher BM, et al. Nat Rev Neurol. 2021 Nov;17(11):689-701. doi: 10.1038/s41582-021-00549-x. Epub 2021 Sep 14. Nat Rev Neurol. 2021. PMID: 34522039 Free PMC article. Review.
Dysregulation of the immune system is a cardinal feature of Alzheimer disease (AD), and a considerable body of evidence indicates pathological alterations in central and peripheral immune responses that change over time. ...We established a whitepaper workgroup to d …
Dysregulation of the immune system is a cardinal feature of Alzheimer disease (AD), and a considerable body of evidence indica …
Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.
Balázs N, Bereczki D, Kovács T. Balázs N, et al. Ideggyogy Sz. 2021 Nov 30;74(11-12):379-387. doi: 10.18071/isz.74.0379. Ideggyogy Sz. 2021. PMID: 34856086 Free article. Review. English.
Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer's therapy for approximately two decades and over the years, more and more experience has been gained on their use in non-Alzheimer's dementias too. The aim of our work was …
Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer's therapy for approximately two decades and ov …
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Berry S, Kramer LD, Berry DA. Dhadda S, et al. Alzheimers Res Ther. 2022 Dec 9;14(1):182. doi: 10.1186/s13195-022-01129-x. Alzheimers Res Ther. 2022. PMID: 36482412 Free PMC article. Clinical Trial.
The primary efficacy endpoint was change from baseline in the Alzheimer's Disease Composite Score (ADCOMS) at 12 months with Bayesian analyses. The key secondary endpoints were ADCOMS at 18 months and Clinical Dementia Rating-Sum-of-Boxes (CDR-SB) and Alzh …
The primary efficacy endpoint was change from baseline in the Alzheimer's Disease Composite Score (ADCOMS) at 12 months …
Translational Research in Alzheimer's and Prion Diseases.
Di Fede G, Giaccone G, Salmona M, Tagliavini F. Di Fede G, et al. J Alzheimers Dis. 2018;62(3):1247-1259. doi: 10.3233/JAD-170770. J Alzheimers Dis. 2018. PMID: 29172000 Free PMC article. Review.
This information can be used to improve clinical trial designs and outcomes that will accelerate drug development, and to discover novel biomarkers which can be efficiently employed to early recognize neurological disorders and provide information regarding the effects of drugs o …
This information can be used to improve clinical trial designs and outcomes that will accelerate drug development, and to discover novel bio …
Advancing Alzheimer's research: A review of big data promises.
Zhang R, Simon G, Yu F. Zhang R, et al. Int J Med Inform. 2017 Oct;106:48-56. doi: 10.1016/j.ijmedinf.2017.07.002. Epub 2017 Jul 24. Int J Med Inform. 2017. PMID: 28870383 Free PMC article. Review.
OBJECTIVE: To review the current state of science using big data to advance Alzheimer's disease (AD) research and practice. In particular, we analyzed the types of research foci addressed, corresponding methods employed and study findings report …
OBJECTIVE: To review the current state of science using big data to advance Alzheimer's disease (AD) research an …
Data Platform for the Research and Prevention of Alzheimer's Disease.
An N, Jin L, Yang J, Yin Y, Jiang S, Jing B, Au R. An N, et al. Adv Exp Med Biol. 2017;1028:55-78. doi: 10.1007/978-981-10-6041-0_4. Adv Exp Med Biol. 2017. PMID: 29058216 Review.
With the rapid increase in global aging, Alzheimer's disease has become a major burden in both social and economic costs. ...In this chapter, we discuss an ongoing effort to build a data platform to harness these data to help research and prevention of …
With the rapid increase in global aging, Alzheimer's disease has become a major burden in both social and economic cost …
161,923 results
You have reached the last available page of results. Please see the User Guide for more information.